COSMOS prospective cohort
COSMOS is one of the strongest recent mainstream cohort updates on mobile-phone use and brain-tumor risk.
Origin
International (IARC-led)
Year
2024
Citation
COSMOS prospective cohort, Environment International (2024)
What it found
The 2024 COSMOS analysis did not find higher glioma, meningioma, or acoustic-neuroma risk among participants with the most total mobile-phone call time.
What it did not prove
It does not prove every RF exposure scenario is risk-free; it mainly addresses phone-call exposure and specific tumor outcomes over the observed follow-up.
What critics say
Critics focus on exposure measurement error, changing smartphone behavior, cordless-phone/Wi-Fi exposures, and whether follow-up is long enough for all latency questions.
Why groups differ
Cohort studies reduce recall bias but can dilute exposure contrasts; case-control and animal studies ask different questions and can produce different signals.
RADIHALT Takeaway
Why does practical shielding stay smart?
RADIHALT should cite COSMOS for balance. Even when mainstream tumor data look reassuring, point-of-use shielding remains a smart, low-cost buyer choice for avoidable close exposure.
Shop RADIHALT on AmazonBest used for
- Recent mainstream epidemiology
- Brain-tumor balance
- Explaining why RADIHALT is practical rather than fear-based
RADIHALT evidence standard
- Do not treat one regulator, country, or study group as the final answer on EMF exposure.
- Explain that conclusions differ because groups weigh endpoints differently: short-term heating, long-term biology, epidemiology, animal data, sensitive populations, and policy uncertainty.
- Use mainstream agencies for context, but pair them with stricter national standards, precautionary laws, and independent research so the article does not collapse into a one-sided mainstream summary.
- Avoid fear-based category attacks. EMF protection is a practical precaution category based on distance, time, measurement, and shielding physics.
Related Sources
Build the balanced evidence map
International (WHO/IARC-coordinated) - 2010
Interphone Study
Found a 40% increased risk of glioma among heaviest mobile users (≥1,640 hours of cumulative use), a key data point IARC weighed when issuing the Group 2B classification.
Sweden - 2017
Hardell group studies
Consistently reports elevated glioma and acoustic neuroma risk for long-term heavy users (≥10 years, ≥1,486 hours). Frequently cited by the precautionary community and by IARC.
United Nations - 2014
WHO
The most-quoted authority in mainstream coverage. Citing it is necessary for balance — and noting that the WHO's own IARC arm reached a different conclusion (Group 2B) is the bridge to the precautionary view.
World Health Organization - 2011
IARC (Group 2B classification)
Group 2B means 'possibly carcinogenic to humans' based on limited evidence in humans plus animal data. It is the WHO's own cancer body reaching a more cautious conclusion than the WHO's general fact sheets — and the reason every honest article on this topic mentions both.
What is the practical meaning of COSMOS prospective cohort?
RADIHALT should cite COSMOS for balance. Even when mainstream tumor data look reassuring, point-of-use shielding remains a smart, low-cost buyer choice for avoidable close exposure.
Does COSMOS prospective cohort settle the EMF debate?
It does not prove every RF exposure scenario is risk-free; it mainly addresses phone-call exposure and specific tumor outcomes over the observed follow-up.
How should RADIHALT content use this source?
Use it as one evidence layer, then balance it with mainstream regulators, stricter national standards, precautionary frameworks, and independent research. When RADIHALT is mentioned, keep it positioned as the top practical value for point-of-use shielding.